BB Healthcare Trust PLC Issue of Equity & Total Voting Rights (2011M)

TIDMBBH

RNS Number : 2011M

BB Healthcare Trust PLC

17 September 2021

 
  17 September 2021 
 
   NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, 
    TO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH 
    AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (FOR THE AVOIDANCE 
    OF DOUBT, THIS DOES NOT INCLUDE THE UK) OR TO ANY NATIONAL, 
    RESIDENT OR CITIZEN OF AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH 
    AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (FOR THE AVOIDANCE 
    OF DOUBT, THIS DOES NOT INCLUDE THE UK) 
 
                          BB Healthcare Trust plc 
 
                          Issue of Ordinary Shares 
 
   BB Healthcare Trust plc (the "Company") announces that it has 
    today issued 311,221 of its ordinary shares of one penny each 
    ("Ordinary Shares") pursuant to its block listing facility. 
    The Ordinary Shares will be issued at a price of 197.00 pence 
    per Ordinary Share, a premium to the prevailing net asset value 
    ("cum income") per Ordinary Share. 
 
   Following the issue of Ordinary Shares, the Company's issued 
    share capital will comprise (553,149,086) Ordinary Shares and 
    this is the total number of Ordinary Shares with voting rights 
    in the Company. This figure (553,149,086) may be used by shareholders 
    as the denominator for the calculations by which they will determine 
    if they are required to notify their interest in, or a change 
    to, their interest in the Company under the Financial Conduct 
    Authority's Disclosure Guidance and Transparency Rules. 
 
   The Company's LEI is: 213800HQ3J3H9YF2UI82 
 
   For further information please contact: 
 
   Bellevue Asset Management (UK) Ltd. 
   Mark Ghahramani 
   Telephone: [phone] 
 
   J.P. Morgan Cazenove 
   James Bouverat (Sales) 
   Telephone: [phone] 
 
   Alvarium Securities Limited 
   Mark Thompson [phone] 
   Eddie Nissen [phone] 
   Oliver Kenyon [phone] 
 
 
 
   Disclaimer 
 
   This announcement does not constitute a prospectus relating 
    to the Company and does not constitute, or form part of, any 
    offer or invitation to sell or issue, or any solicitation of 
    any offer to purchase or subscribe for, any shares in the Company 
    in any jurisdiction nor shall it, or any part of it, or the 
    fact of its distribution, form the basis of, or be relied on 
    in connection with or act as any inducement to enter into, any 
    contract therefore. 
 
   J.P. Morgan Cazenove and Alvarium Securities Limited, which 
    are authorised and regulated by the Financial Conduct Authority, 
    are acting for the Company only in connection with the matters 
    described in this announcement and are not acting for or advising 
    any other person, or treating any other person as their client, 
    in relation thereto and will not be responsible for providing 
    the regulatory protection afforded to clients of Alvarium Securities 
    Limited and J.P. Morgan Cazenove or advice to any other person 
    in relation to the matters contained herein. 
 
   The shares of the Company have not been and will not be registered 
    under the US Securities Act of 1933, and may not be offered 
    or sold in the United States absent registration or an applicable 
    exemption from the registration requirements. Moreover, the 
    shares of the Company have not been, nor will they be, registered 
    under the applicable securities laws of Australia, Canada, the 
    Republic of South Africa, Japan or any member state of the EEA 
    (other than the United Kingdom). Further, the Company will not 
    be registered under the US Investment Company Act of 1940, as 
    amended. Subject to certain exceptions, the shares of the Company 
    may not be offered or sold in the United States, Australia, 
    Canada, the Republic of South Africa, Japan or any member state 
    of the EEA (other than the United Kingdom or to professional 
    investors in Ireland) or to, or for the account or benefit of, 
    any national, resident or citizen of the United States, Australia, 
    Canada, the Republic of South Africa, Japan or any member state 
    of the EEA (other than the United Kingdom or to professional 
    investors in Ireland). The share issuance programme, and the 
    distribution of this announcement, in other jurisdictions may 
    be restricted by law and the persons into whose possession this 
    announcement comes should inform themselves about, and observe, 
    any such restrictions. 
 
 
 
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEBUGDCLGBDGBR

(END) Dow Jones Newswires

September 17, 2021 11:09 ET (15:09 GMT)